Ganoderic acid targeting multiple receptors in cancer: in silico and in vitro study

Croce CM. Oncogenes and cancer. N Engl J Med. 2008;358(5):502–11.

Anand SS, Gill BS. Breakthroughs in epigenetics. Pharm Tutor. 2015;3(7):16–24.

Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990;61(2):203–12.

Negi A, Gill B. Success stories of enolate form of drugs. Pharm Tutor. 2013;1(2):45–53.

Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer. 2001;8(3):161–73.

Gill BS, Kumar S. Triterpenes in cancer: significance and their influence. Mol Biol Rep. 2016;43(9):881–96. doi: 10.1007/s11033-016-4032-9 .

Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103(2):211–25.

Gill BS, Alex JM, Kumar S. Missing link between microRNA and prostate cancer. Tumor Biol. 2016;37(5):5683–704.

Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet. 1993;9(4):138–41.

Negi ABG, Anand SS. Tilling: versatile reverse genetic tool. Pharma Tutor. 2014;2(1):26–32.

Hollosy F, Keri G. Plant-derived protein tyrosine kinase inhibitors as anticancer agents. Curr Med Chem Anticancer Agents. 2004;4(2):173–97.

Gill BS, Sharma P, Kumar R, Kumar S. Misconstrued versatility of Ganoderma lucidum: a key player in multi-targeted cellular signaling. Tumor Biol. 2015;37(3):2789–804.

Yuen JW, Gohel MDI. Anticancer effects of Ganoderma lucidum: a review of scientific evidence. Nutr Cancer. 2005;53(1):11–7.

Gill BS, Kumar S. Differential algorithms-assisted molecular modeling-based identification of mechanistic binding of ganoderic acids. Med Chem Res. 2015;24(9):3483–93.

Liu J, Shiono J, Shimizu K, Kukita A, Kukita T, Kondo R. Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor. Bioorg Med Chem Lett. 2009;19(8):2154–7.

Yao X, Li G, Xu H, Lü C. Inhibition of the JAK-STAT3 signaling pathway by ganoderic acid A enhances chemosensitivity of HepG2 cells to cisplatin. Planta Med. 2012;78(16):1740–8.

Chen N-H, Liu J-W, Zhong J-J. Ganoderic acid Me inhibits tumor invasion through down-regulating matrix metalloproteinases 2/9 gene expression. J Pharmacol Sci. 2008;108(2):212–6.

Hong R-L, Spohn WH, Hung M-C. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin Cancer Res. 1999;5(7):1884–91.

Huang YT, Hwang JJ, Lee PP, Ke FC, Huang JH, Huang CJ, et al. Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis‐associated properties in A431 cells overexpressing epidermal growth factor receptor. Br J Pharmacol. 1999;128(5):999–1010.

Kwon HJ, Shim JS, Kim JH, Cho HY, Yum YN, Kim SH, et al. Betulinic acid inhibits growth factor‐induced in vitro angiogenesis via the modulation of mitochondrial function in endothelial cells. Cancer Sci. 2002;93(4):417–25.

Zhang X, Mukerji R, Samadi AK, Cohen MS. Down-regulation of estrogen receptor-alpha and rearranged during transfection tyrosine kinase is associated with withaferin a-induced apoptosis in MCF-7 breast cancer cells. BMC Complement Altern Med. 2011;11(1):84.

Zhang W, Hong D, Zhou Y, Zhang Y, Shen Q, Li J-Y, et al. Ursolic acid and its derivative inhibit protein tyrosine phosphatase 1B, enhancing insulin receptor phosphorylation and stimulating glucose uptake. BBA Gen Subjects. 2006;1760(10):1505–12.

Mu X, Shi W, Sun L, Li H, Jiang Z, Zhang L. Pristimerin, a triterpenoid, inhibits tumor angiogenesis by targeting VEGFR2 activation. Molecules. 2012;17(6):6854–68.

Jorgensen WL, Maxwell DS, Tirado-Rives J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc. 1996;118(45):11225–36.

Jorgensen WL, Tirado-Rives J. The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. J Am Chem Soc. 1988;110(6):1657–66.

Shivakumar D, Williams J, Wu Y, Damm W, Shelley J, Sherman W. Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. J Chem Theory Comput. 2010;6(5):1509–19.

Repasky MP, Shelley M, Friesner RA. Flexible ligand docking with GLIDE. Curr Protoc Bioinform. 2007;8.12.1–8.12.36

Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. GLIDE: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739–49.

Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem. 2006;49(21):6177–96.

Jorgensen WL, Duffy EM. Prediction of drug solubility from structure. Adv Drug Deliv Rev. 2002;54(3):355–66.

Singh P, Bast F. High-throughput virtual screening, identification and in vitro biological evaluation of novel inhibitors of signal transducer and activator of transcription 3. Med Chem Res. 2015;24(6):2694–708.

Gill BS, Navgeet, Kumar S. Ganoderic acid A targeting β-catenin in Wnt signaling pathway: in silico and in vitro study. Interdisciplinar Sci Comput Life Sci. 2016. doi: 10.1007/s12539-016-0182-7 .